Insider and congress filings
Johnson & Johnson (JNJ)
About Johnson & Johnson
from the company's filings and listing- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Joaquin Duato
- Employees
- 141,700
- Listed since
- -
- Market value
- $643.6B
- Price to earnings
- 30.9
- Earnings per share
- $8.62
- Dividend yield
- 1.98%
Earnings
6 reported quarters · next on Oct 13, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 15, 2026 | $2.90 | $2.84 | $25.3B | $25.1B | EPS beatRevenue in line |
| Q1 FY2026reported Apr 14, 2026 | $2.70 | $2.68 | $24.1B | $23.6B | EPS in lineRevenue beat |
| Jan 21, 2026 | $2.46 | $2.46 | $24.6B | $24.1B | EPS in lineRevenue beat |
| Q3 FY2025reported Oct 14, 2025 | $2.80 | $2.76 | $24.0B | $23.8B | EPS in lineRevenue in line |
| Q2 FY2025reported Jul 16, 2025 | $2.77 | $2.68 | $23.7B | $22.9B | EPS beatRevenue beat |
| Q1 FY2025reported Apr 15, 2025 | $2.77 | $2.58 | $21.9B | $21.6B | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Mar 11, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| J. DuatoChairman/CEO | $1.6M | $15.0M | $16.1M | $32.8M |
| J. WolkEVP, CFO | $1.2M | $6.3M | $6.9M | $14.4M |
| J. TaubertEVP, WWC Innovative Medicine | $1.2M | $6.2M | $6.6M | $14.0M |
| J. ReedEVP, Innovative Medicine, R&D | $1.2M | $6.2M | $4.8M | $12.2M |
| T. SchmidEVP, WWC, MedTech | $942K | $3.4M | $5.0M | $9.3M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $53.9B | 212,098,264 | -0.6% | 8.69% |
| Vanguard Capital Management LLC | $39.9B | 157,226,374 | +0.4% | 6.44% |
| State Street Corp | $34.0B | 133,776,025 | +0.2% | 5.48% |
| Vanguard Portfolio Management LLC | $16.3B | 64,370,816 | +1.3% | 2.64% |
| Jpmorgan Chase & Co | $15.1B | 58,301,609 | -7.6% | 2.39% |
| Geode Capital Management, LLC | $15.0B | 59,086,417 | -0.1% | 2.42% |
| Morgan Stanley | $11.4B | 44,808,254 | +0.2% | 1.84% |
| Norges Bank | $8.1B | 31,825,084 | +100.0% | 1.30% |
| State Farm Mutual Automobile Insurance Co | $8.0B | 31,590,952 | 0.0% | 1.29% |
| Northern Trust Corp | $7.3B | 28,792,064 | -1.8% | 1.18% |
| Bank Of America Corp | $6.0B | 23,438,141 | -8.1% | 0.96% |
| Price T Rowe Associates Inc | $5.8B | 22,996,878 | +39.5% | 0.94% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
11 filings of 299 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Timothy SchmidEVP, WW Chair, Medtech | Sold | 22,527 | $274.74 | $6.2M | Sep 2, 2026 | 2d |
| Jennifer L. TaubertEVP, WWC. Innovative Medicine | Sold | 15,000 | $263.36 | $4.0M | Aug 17, 2026 | 1d |
| Joaquin DuatoCEO and Chairman of the Board | Sold · 2 lines | 123,291 | $261.17 | $32.2M | Aug 13, 2026 | 1d |
| Elizabeth ForminardEVP, Chief Legal Officer | Sold · 2 lines | 15,918 | $257.00 | $4.1M | Aug 6, 2026 | 1d |
| Joaquin DuatoCEO and Chairman of the Board | Sold · 2 lines | 48,480 | $258.15 | $12.5M | Aug 5, 2026 | 2d |
| Vanessa BroadhurstEVP, Global Corp Affairs | Sold | 23,054 | $251.27 | $5.8M | Jul 20, 2026 | 1d |
| Kathryn E. WengelEVP, Chief TO and Risk Officer | Sold | 10,000 | $241.15 | $2.4M | Jun 11, 2026 | 1d |
| Robert J. DeckerVP Corporate Controller | Sold | 4,075 | $247.87 | $1.0M | Feb 27, 2026 | 4d |
| Timothy SchmidEVP, WW Chair, Medtech | Sold | 1,322 | $245.66 | $325K | Feb 20, 2026 | 3d |
| James D. SwansonEVP, CIO | Sold | 20,521 | $242.70 | $5.0M | Feb 17, 2026 | 1d |
| James D. SwansonEVP, CIO | Sold · 2 lines | 41,559 | $243.73 | $10.1M | Feb 13, 2026 | 5d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in JNJ
20 disclosures of 306 on record · median 27d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +3.0%S&P -1.4% · vs S&P 500 +4.4% | Aug 7, 2026 | Sep 4, 2026 | 28d |
| Richard McCormick | Stock | Sale | $1,001 - $15,000 | +4.4%S&P +2.8% · vs S&P 500 +1.6% | Jul 30, 2026 | Aug 14, 2026 | 15d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +7.3%S&P +2.7% · vs S&P 500 +4.6% | Jul 20, 2026 | Aug 7, 2026 | 18d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $15,001 - $50,000 | +11.1%S&P +20.2% · vs S&P 500 -9.1% | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $1,001 - $15,000 | +11.0%S&P +21.2% · vs S&P 500 -10.2% | Mar 30, 2026 | Jul 21, 2026 | 113d |
| Thomas H. Kean, Jr. | Stock | Sale | $1,001 - $15,000 | +3.3%S&P +2.9% · vs S&P 500 +0.4% | Jun 29, 2026 | Jul 15, 2026 | 16d |
| Thomas H. Kean, Jr. | Stock | Sale | $1,001 - $15,000 | +19.8%S&P +0.4% · vs S&P 500 +19.5% | Jun 2, 2026 | Jul 15, 2026 | 43d |
| Lloyd Doggett | Stock | Purchase | $1,001 - $15,000 | +12.7%S&P +3.4% · vs S&P 500 +9.3% | Jun 9, 2026 | Jul 6, 2026 | 27d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +19.8%S&P +0.4% · vs S&P 500 +19.5% | Jun 2, 2026 | Jul 6, 2026 | 34d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +13.6%S&P +1.6% · vs S&P 500 +12.0% | Jun 16, 2026 | Jul 6, 2026 | 20d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +17.6%S&P +5.8% · vs S&P 500 +11.8% | May 1, 2026 | Jun 9, 2026 | 39d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +17.8%S&P +3.2% · vs S&P 500 +14.7% | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Purchase | $15,001 - $50,000 | +12.2%S&P +11.1% · vs S&P 500 +1.1% | Apr 13, 2026 | May 11, 2026 | 28d |
| John BoozmanJoint | Stock | Sale (Partial) | $1,001 - $15,000 | +12.4%S&P +15.5% · vs S&P 500 -3.1% | Mar 19, 2026 | Apr 14, 2026 | 26d |
| Thomas H. Kean, Jr. | Stock | Sale | $1,001 - $15,000 | +11.6%S&P +17.8% · vs S&P 500 -6.2% | Mar 26, 2026 | Apr 13, 2026 | 18d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +11.1%S&P +13.3% · vs S&P 500 -2.2% | Mar 6, 2026 | Apr 7, 2026 | 32d |
| Richard McCormick | Stock | Sale | $1,001 - $15,000 | +13.3%S&P +15.7% · vs S&P 500 -2.4% | Mar 19, 2026 | Apr 7, 2026 | 19d |
| Lloyd Doggett | Stock | Purchase | $1,001 - $15,000 | +9.6%S&P +12.6% · vs S&P 500 -3.0% | Mar 10, 2026 | Apr 6, 2026 | 27d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +12.3%S&P +12.5% · vs S&P 500 -0.2% | Feb 5, 2026 | Mar 9, 2026 | 32d |
| Thomas H. Kean, Jr. | Stock | Sale | $15,001 - $50,000 | +22.3%S&P +10.8% · vs S&P 500 +11.5% | Jan 23, 2026 | Feb 19, 2026 | 27d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
25 of 34 listed · estimate, as of Sep 10, 202634 members report a position (estimated). The largest estimated position is in the $500,001 - $1,000,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Thomas H. Kean, Jr. | Republican · House | $500,001 - $1,000,000 | 15.1% |
| Lloyd Doggett | Democrat · House | $100,001 - $250,000 | 1.6% |
| Ed Case | Democrat · House | $100,001 - $250,000 | 5.2% |
| Kelly Morrison | Democrat · House | $100,001 - $250,000 | 1.3% |
| Scott Franklin | Republican · House | $100,001 - $250,000 | 3.2% |
| Jared Moskowitz | Democrat · House | $100,001 - $250,000 | 2.3% |
| Carol D. Miller | Republican · House | $50,001 - $100,000 | 4.1% |
| David Kustoff | Republican · House | $50,001 - $100,000 | 3.1% |
| Debbie Dingell | Democrat · House | $50,001 - $100,000 | 1.2% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $50,001 - $100,000 | 0.3% |
| J. French Hill | Republican · House | $50,001 - $100,000 | 0.6% |
| Kevin Hern | Republican · House | $50,001 - $100,000 | 0.3% |
| Neal P. Dunn | Republican · House | $50,001 - $100,000 | 1.6% |
| Robert Bresnahan | Republican · House | $50,001 - $100,000 | 0.7% |
| Shelley Moore Capito | Republican · Senate | $50,001 - $100,000 | 3.6% |
| David P. Joyce | Republican · House | $50,001 - $100,000 | 2.1% |
| Randy Fine | Republican · House | $50,001 - $100,000 | 4.5% |
| Marjorie Taylor Greene | Republican · House | $50,001 - $100,000 | 1.6% |
| Angus S. King Jr. | Independent · Senate | $50,001 - $100,000 | 1.3% |
| Bill Hagerty | Republican · Senate | $50,001 - $100,000 | 0.3% |
| Gary C. Peters | Democrat · Senate | $50,001 - $100,000 | 1.6% |
| Susan M. Collins | Republican · Senate | $50,001 - $100,000 | 1.4% |
| Tina Smith | Democrat · Senate | $50,001 - $100,000 | 2.8% |
| Josh Gottheimer | Democrat · House | $50,001 - $100,000 | 0.2% |
| Robert Onder | Republican · House | $15,001 - $50,000 | 0.8% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Timothy SchmidEVP, WW Chair, Medtech | Option exercise | 33,597 | Sep 2, 2026 |
| Thomas CavanaughEVP WW Chair, Innovative Med. | Form 4 | 80,689 | Sep 1, 2026 |
| Thomas CavanaughEVP WW Chair, Innovative Med. | Form 4 | 16,543 | Feb 10, 2023 |
| Thomas CavanaughEVP WW Chair, Innovative Med. | Form 4 | 14,383 | Feb 8, 2024 |
| Thomas CavanaughEVP WW Chair, Innovative Med. | Form 4 | 11,906 | Feb 14, 2025 |
| Jennifer L. TaubertEVP, WWC. Innovative Medicine | Option exercise | 15,000 | Aug 17, 2026 |
| Joaquin DuatoCEO and Chairman of the Board | Option exercise | 123,291 | Aug 13, 2026 |
| Elizabeth ForminardEVP, Chief Legal Officer | Option exercise | 9,344 | Aug 6, 2026 |
| Vanessa BroadhurstEVP, Global Corp Affairs | Option exercise | 23,054 | Jul 20, 2026 |
| Kathryn E. WengelEVP, Chief TO and Risk Officer | Option exercise | 10,000 | Jun 11, 2026 |
| Eugene A. WoodsDirector | Stock award | 161 | Jun 9, 2026 |
| Marillyn A. HewsonDirector | Stock award | 215 | Jun 9, 2026 |
| Daniel E. PintoDirector | Stock award | 134 | Jun 9, 2026 |
| John C. ReedEVP, Innovative Medicine, R&D | Option exercise | 25,255 | May 1, 2026 |
| John C. ReedEVP, Innovative Medicine, R&D | Tax withholding | 11,002 | May 1, 2026 |
| Nadja WestDirector | Stock award | 975 | Apr 23, 2026 |
| Mary C. BeckerleDirector | Stock award | 975 | Apr 23, 2026 |
| Mark A. WeinbergerDirector | Stock award | 975 | Apr 23, 2026 |
| Jennifer A. DoudnaDirector | Stock award | 975 | Apr 23, 2026 |
| Marillyn A. HewsonDirector | Stock award | 975 | Apr 23, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling JNJ?
Across the 11 most recent open-market filings shown here, 0 were purchases and 11 were sales.
Which members of Congress have traded JNJ?
Ro Khanna, Richard McCormick, Alan Armstrong, Thomas H. Kean, Jr., Lloyd Doggett, John Boozman disclosed JNJ transactions in the filings shown here.
Which members of Congress hold JNJ?
34 members of Congress report a position in JNJ in the estimate we hold as of Sep 10, 2026. The three largest estimated positions belong to Thomas H. Kean, Jr., Lloyd Doggett and Ed Case. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is JNJ in the S&P 500 or the Nasdaq 100?
Johnson & Johnson is a current member of the S&P 500, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are JNJ trades disclosed?
Insider filings on this page reached the public a median of 1 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 27 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.